Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Cantor Fitzgerald issued their FY2022 earnings estimates for Aptose Biosciences in a note issued to investors on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biotechnology company will post earnings per share of ($0.60) for the year. Cantor Fitzgerald currently has a “Overweight” […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Aptose Biosciences Inc. (NASDAQ:APTO – Get Rating) (TSE:APS) – Investment analysts at Oppenheimer upped their FY2025 EPS estimates for Aptose Biosciences in a note issued to investors on Tuesday, August 2nd. Oppenheimer analyst M. Biegler now expects that the biotechnology company will earn $0.33 per share for the year, up from their prior forecast of […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Aptose Biosciences (NASDAQ:APTO – Get Rating) and Caribou Biosciences (NASDAQ:CRBU – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings. Institutional and Insider Ownership 34.2% of Aptose Biosciences shares […]